Use of CpG oligodeoxynucleotides as immune adjuvants

Immunological Reviews

Volumn 199, Issue , 2004, Pages 201-216

  Klinman, Dennis M ^a,b   Currie, Debra ^a   Gursel, Ihsan ^a   Verthelyi, Daniela ^a  

^a Center for Biologics Evaluation/Res   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTIGEN; CYTOKINE; DNA; DNA VACCINE; HEPATITIS B VACCINE; LEISHMANIA VACCINE; OLIGODEOXYNUCLEOTIDE DERIVATIVE; OVALBUMIN; PLASMID VECTOR; VACCINE;

ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CELL ACTIVATION; CELL MATURATION; CELL STIMULATION; CLINICAL TRIAL; COMPARATIVE STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FLU LIKE SYNDROME; GENETIC HETEROGENEITY; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTOPOIESIS; MOLECULAR MECHANICS; MUCOSAL IMMUNITY; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEIN VARIANT; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; SPECIES DIFFERENCE; TH1 CELL; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HUMANS; IMMUNIZATION, SECONDARY; OLIGODEOXYRIBONUCLEOTIDES; PLASMIDS; VACCINES, DNA;

EID: 2942549527     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2004.00148.x     Document Type: Review

References (135)

1. Yamamoto S, et al. Antitumor effect of nucleic acid fraction from bacteria. Proc Jpn Soc Immunol 1989;48:272-281.
2. Yamamoto S, et al. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J Immunol 1992;148:4072-4076.
3. Krieg AM, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-548.
4. Klinman DM, Yi A, Beaucage SL, Conover J, Krieg AM. CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and IFNγ. Proc Natl Acad Sci USA 1996;93:2879-2883.
5. Razin A, Friedman J. DNA methylation and its possible biological roles. Prog Nucleic Acid Res Mol Biol 1981;25:33-52.
6. Cardon LR, Burge C, Clayton DA, Karlin S. Pervasive CpG suppression in animal mitochondrial genomes. Proc Natl Acad Sci USA 1994;91:3799-3803.
7. Wagner H. Bacterial CpG-DNA activates immune cells to signal 'infectious danger'. Adv Immunol 1999;73:329-368.
8. Sun S, Zhang X, Tough DF, Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 1998;188:2335-2342.
9. Stacey KJ, Sweet MJ, Hume DA. Macrophages ingest and are activated by bacterial DNA. J Immunol 1996;157:2116-2120.
10. Ballas ZD, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996;157:1840-1847.
11. Roman M, et al. Immunostimulatory DNA sequences function as T helper-1 promoting adjuvants. Nat Med 1997;3:849-854.
12. Halpern MD, Kurlander RJ, Pisetsky DS. Bacterial DNA induces murine interferon-gamma production by stimulation of IL-12 and tumor necrosis factor-alpha. Cell Immunol 1996;167:72-78.
13. Gursel M, Verthelyi D, Gursel I, Ishii KJ, Klinman DM. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotides. J Leukoc Biol 2002;71:813-820.
14. Medzhitov R, Janeway CA. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1998;91:295-298.
15. Underhill DM, Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol 2002;14:103-110.
16. Vasselon T, Detmers PA. Toll receptors: a central element in innate immune responses. Infect Immun 2002;70:1033-1041.
17. Hemmi H, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-745.
18. Takeshita F, et al. Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 2001;167:3555-3558.
19. Bauer S, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001;98:9237-9242.
20. Hornung V, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002;168:4531-4537.
21. Yi AK, et al. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J Immunol 1998;160:4755-4761.
22. Hacker H, et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J 1998;17:6230-6240.
23. Takeshita F, Ishii KJ, Ueda A, Ishigatsubo Y, Klinman DM. Positive and negative regulatory elements contribute to CpG oligonucleotide-mediated regulation of human IL-6 gene expression. Eur J Immunol 2000;30:108-116.
24. Yamamoto M, et al. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol 2002;169:6668-6672.
25. Takeshita F, Klinman DM. CpG ODN-mediated regulation of IL-12 p40 transcription. Eur J Immunol 2000;30:1967-1976.
26. Hacker H, et al. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF) 6. J Exp Med 2000;191:595-600.
27. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000;406:782-787.
28. Rankin R, et al. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev 2001;11:333-340.
29. Kadowaki N, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001;194:863-869.
30. Krug A, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001;31:3026-3037.
31. Bauer M, et al. Bacterial CpG DNA triggers activation and maturation of human CD11c(-), CD123(+) dendritic cells. J Immunol 2001;166:5000-5007.
32. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM. Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. J Immunol 2001;166:2372-2377.
33. Hartmann G, et al. Delineation of a CpG phosphorothioate oligodeoxinucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000;164:1617-1624.
34. Hartmann G, et al. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol 2003;33:1633-1641.
35. Marshall JD, et al. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol 2003;73:781-792.
36. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 2000;164:944-952.
37. Verthelyi D, et al. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol 2002;168:1659-1663.
38. Verthelyi D, Klinman DM. Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin Immunol 2003;109:64-71.
39. Davis HL, et al. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 2000;18:1920-1924.
40. Broide DH, et al. Systemic administration of immunostimulatory DNA sequences mediates reversible inhibition of Th2 responses in a mouse model of asthma. J Clin Immunol 2001;21:175-182.
41. Bauer M, Heeg K, Wagner H, Lipford GB. DNA activates human immune cells through a CpG sequence-dependent manner. Immunology 1999;97:699-705.
42. Bohle B, Orel L, Kraft D, Ebner C. Oligodeoxynucleotides containing CpG motifs induce low levels of TNF-alpha in human B lymphocytes: possible adjuvants for Th1 responses. J Immunol 2001;166:3743-3748.
43. Leifer CA, Verthelyi D, Klinman DM. CpG ODN mixtures optimally activate human PBMC. Interfaces between innate and adaptive immunity. Keystone Symp 2001,22-27.
44. Leifer C, Verthelyi D, Klinman DM. Human response to immunostimulatory CpG oligondeoxynucleotides. J Immunother 2003;26:313-318.
45. Klinman DM, Currie D. Hierarchical recognition of CpG motifs expressed by immunostimulatory oligodeoxynucleotides. Clin Exp Immunol 2003;133:227-232.
46. Klinman DM. Therapeutic applications of CpG-containing oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev 1998;8:181-184.
47. Tighe H, et al. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol 2000;30:1939-1947.
48. Gursel I, Gursel M, Ishii KJ, Klinman DM. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol 2001;167:3324-3328.
49. Shirota H, et al. Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J Immunol 2001;167:66-74.
50. Klinman DM, Barnhart KM, Conover J. CpG motifs as immune adjuvants. Vaccine 1999;17:19-25.
51. Lipford GB, et al. Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur J Immunol 1997;27:3420-3426.
52. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in rumor antigen immunization. Proc Natl Acad Sci USA 1997;94:10833-10837.
53. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper (Th1) immunity. J Exp Med 1997;186:1623-1631.
54. Chu RS, Askew D, Harding CV. CpG DNA switches on Th1 immunity and modulates antigen-presenting cell function. Curr Top Microbiol Immunol 2000;247:199-210.
55. Askew D, Chu RS, Krieg AM, Harding CV. CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. J Immunol 2000;165:6889-6895.
56. Davis HL, et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 1998;160:870-876.
57. Tighe H, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000;106:124-134.
58. Moldoveanu Z, Love-Homan L, Huang WQ, Krieg AM. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 1998;16:1216-1224.
59. Kovarik J, et al. CpG oligonucleotides can circumvent the TH2 polorization of neonatal responses to vaccines but fail to fully redirect TH2 responses established by neonatal priming. J Immunol 1999;162:1611-1617.
60. McCluskie MJ, Davis HL. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 1998;161:4463-4466.
61. Millan CLB, Weeratna R, Krieg AM, Siegrist CA, Davis HL. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci USA 1998;95:15553-15558.
62. Eastcott JW, et al. Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid. Vaccine 2001;19:1636-1642.
63. Oxenius A, Martinic MM, Hengartner H, Klenerman P. CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. J Virol 1999;73:4120-4126.
64. Branda RF, et al. Amplification of antibody production by phosphorothioate oligodeoxynucleotides. J Lab Clin Med 1996;128:329-338.
65. Prince GA, et al. Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J Virol 2003;77:13156-13160.
66. Klinman DM, Xie H, Little SF, Currie D, Ivins B. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine (in press).
67. Ashkar AA, Bauer S, Mitchell WJ, Vieira J, Rosenthal KL. Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J Virol 2003;77:8948-8956.
68. Horner AA, et al. Immunostimulatory DNA is a potent mucosal adjuvant. Cell Immunol 1998;190:77-82.
69. McCluskie MJ, Davis HL. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine 2000;19:413-422.
70. Sterzl J, Silverstein AM. Developmental aspects of immunity. Adv Immunol 1967;6:337-459.
71. Hunt DW, Huppertz HI, Jiang HJ, Petty RE. Studies of human cord blood dendritic cells: evidence for functional immaturity. Blood 1994;84:4333-4343.
72. Mor G, et al. Induction of neonatal tolerance by plasmid DNA vaccination of mice. J Clin Invest 1997;98:2700-2705.
73. Ishii KJ, Weiss WR, Klinman DM. Prevention of neonatal tolerance by a plasmid encoding granulocyte-macrophage colony stimulating factor. Vaccine 1999;18:703-710.
74. Zhang J, Silvestri N, Whitton JL, Hassett DE. Neonates mount robust and protective adult-like CD8(+) T-cell responses to DNA vaccines. J Virol 2002;76:11911-11919.
75. Bot A, Bot S, Bona C. Enhanced protection against influenza virus of mice immunized as newborns with a mixture of plasmids expressing hemagglutinin and nucleoprotein. Vaccine 1998;16:1675-1682.
76. von Stebut E, et al. Leishmania major infected murine langerhans cell-like dendritic cells from susceptible mice release IL-12 after infection and vaccinate against experimental cutaneous leishmaniasis. Eur J Immunol 2000;30:3498-3506.
77. Jones TR, et al. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenic vaccine in Aotus monkeys. Vaccine 1999;17:3065-3071.
78. + (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood 2001;98:3016-3021.
79. Azzoni L, et al. Sustained impairment of IFN-gamma secretion in suppressed HIV-infected patients despite mature NK cell recovery: evidence for a defective reconstitution of innate immunity. J Immunol 2002;168:5764-5770.
80. Chehimi J, et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 2002;168:4796-4801.
81. Corbett EL, et al. HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet 2002;359:2177-2187.
82. Diamant EP, Schechter C, Hodes DS, Peters VB. Immunogenicity of hepatitis B vaccine in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1993;12:877-878.
83. + lymphocyte count and vaccination schedule. Int J STD AIDS 1996;7:490-494.
84. Verthelyi D, et al. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from leishmania infection. J Immunol 2003;170:4717-4723.
85. Halperin SA, et al. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003;21:2461-2467.
86. Ulmer JB, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein (see comments). Science 1993;259:1745-1749.
87. Sedegah M, Hedstrom R, Hobart P, Hoffman SL. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci USA 1994;91:9866-9870.
88. Cox GJ, Zamb TJ, Babiuk LA. Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA. J Virol 1993;67:5664-5667.
89. Wang B, et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90:4156-4160.
90. Tang D, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992;356:152-154.
91. Wolff JA, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-1468.
92. Manthorpe M, et al. Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. Hum Gene Ther 1993;4:419-431.
93. Mor G, et al. Complexity of the cytokine and antibody response elicited by immunizing mice with Plasmodium yoelii circumsporozoite protein plasmid DNA. J Immunol 1995;155:2039-2046.
94. Wang R, et al. Induction of antigen specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998;282:476-480.
95. Calarota S, et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1 infected patients. Lancet 1998;351:1320-1325.
96. Sato Y, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996;273:352-354.
97. Snapper CM, Paul WE. B cell stimulatory factor-1 (IL-4) prepares resting murine B cells to secrete IgG1 upon subsequent stimulation with bacterial lipopolysaccharide. J Immunol 1987;139:10-18.
98. Finkleman FD, Katona IM, Mosmann TR, Coffman RC. Interferon gamma regulates the isotype of Ig secreting during in vivo humoral responses. J Immunol 1988;140:1022-1030.
99. Klinman DM, Yamshchikov G, Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 1997;158:3635-3642.
100. Weeratna R, Brazolot CL, Millan B, Krieg AM, Davis HL. Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev 1998;8:351-356.
101. Jakob T, Walker PS, Krieg AM, Udey MC, Vogel JC. Activation of cutaneous dendritic cells by CpG containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 1998;161:3042-3049.
102. Sparwasser T, et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 1998;28:2045-2054.
103. Krieg AM, et al. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci USA 1998;95:12631-12636.
104. Gursel I, et al. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol 2003;171:1393-1400.
105. Krieg AM, Davis HL. Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther 2001;3:15-24.
106. Spies B, et al. Vaccination with plasmid DNA activates dendritic cells via TLR9 but functions in TLR9-deficient mice. J Immunol 2003;171:5908-5912.
107. Kojima Y, et al. Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine. Vaccine 2002;20:2857-2865.
108. Rodriguez EG, Vazquez DM, Herrera AM, Duarte CA. Enhanced cell-mediated IFN-gamma-secreting activity against the HIV-1IIIB V3 peptide of the TAB9 multiepitope after DNA vaccine backbone engineering. Biochem Biophys Res Commun 2003;308:713-718.
109. Gilkeson GS, Riuz P, Howell D, Lefkowith JB, Pisetsky DS. Induction of immune-mediated glomerulonephritis in normal mice immunized with bacterial DNA. Clin Immunol Immunopathol 1993;68:283-292.
110. Gilkeson GS, Pippen AM, Pisetsky DS. Induction of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA. J Clin Invest 1995;95:1398-1402.
111. Steinberg AD, Krieg AM, Gourley MF, Klinman DM. Theoretical and experimental approaches to generalized autoimmunity. Immunol Rev 1990;118:129-163.
112. Klinman DM. Polyclonal B cell activation in lupus-prone mice precedes and predicts the development of autoimmune disease. J Clin Invest 1990;86:1249-1254.
113. Linker-Israeli M, et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. J Immunol 1991;147:117-123.
114. Krieg AM. CpG DNA: a pathogenic factor in systemic lupus erythematosus? J Clin Immunol 1995;15:284-292.
115. Yi A-K, Hornbeck P, Lafrenz DE, Krieg AM. CpG DNA rescue of murine B lymphoma cells from anti-IgM induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xl. J Immunol 1996;157:4918-4925.
116. Mor G, et al. Do DNA vaccines induce autoimmune disease? Hum Gene Ther 1997;8:293-300.
117. Katsumi A, et al. Humoral and cellural immunity to an encoded protein induced by direct DNA injection. Hum Gene Ther 1994;5:1335-1339.
118. Gilkeson GS, et al. Effects of bacterial DNA on cytokine production by (NZB/NZW) F1 mice. J Immunol 1998;161:3890-3895.
119. Segal BM, Klinman DM, Shevach EM. Microbial products induce autoimmune disease by an IL-12 dependent process. J Immunol 1997;158:5087-5091.
120. Segal BM, Chang JT, Shevach EM. CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalotogenic T cells in vivo. J Immunol 2000;164:5683-5688.
121. Bachmaier K, et al. Chlamydia infections and heart disease linked through antigenic mimicry. Science 1999;283:1335-1339.
122. Zeuner RA, Verthelyi D, Gursel M, Ishii KJ, Klinman DM. Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis. Arthritis Rheum 2003;48:1701-1707.
123. Sparwasser T, et al. Bacterial DNA causes septic shock. Nature 1997;386:336-338.
124. Cowdery JS, Chace JH, Yi A-K, Krieg AM. Bacterial DNA induces NK cells to produce IFN gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol 1996;156:4570-4575.
125. Hartmann G, Krug A, Waller K, Endres S. Oligodeoxynucleotides enhance LPS-stimulated synthesis of TNF: dependence on phosphorothioate modification and reversal by heparin. Mol Med 1996;2:429-438.
126. Klinman DM, et al. DNA vaccines: safety and efficacy issues. Springer Semin Immunopathol 1997;19:245-256.
127. Yacyshyn BR, et al. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Aliment Pharmacol Ther 2002;16:1761-1770.
128. Liu MA. DNA vaccines: a review. J Intern Med 2003;253:402-410.
129. Klinman DM, et al. Immunotherapeutic applications of CpG-containing oligodeoxynucleotides. Drug News Perspect 2000;13:289-296.
130. Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2003;2: 305-315.
131. Sparwasser T, et al. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-a-mediated shock. Eur J Immunol 1997;27:1671-1679.
132. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996;272:50-53.
133. Klinman DM, Verthelyi D, Takeshita F, Ishii KJ. Immune recognition of foreign DNA. a cure for bioterrorism? Immunity 1999;11:123-129.
134. von Hunolstein C, et al. The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-haemophilus influenzae type b glycoconjugates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines. Vaccine 2001;19:3058-3066.
135. Al Mariri A, et al. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect Immun 2001;69:4816-4822.